Cyclooxygenase inhibition and thrombogenicity (Q28175694)

American Journal of Medicine

Europe PubMed Central

title

Cyclooxygenase inhibition and thrombogenicity (English)

0 references

author name string

F Catella-Lawson

series ordinal

1

0 references

L J Crofford

series ordinal

2

0 references

language of work or name

English

0 references

publication date

19 February 2001

0 references

published in

0 references

volume

110 Suppl 3A

0 references

page(s)

28S-32S

0 references

cites work

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Platelet activation in unstable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Paired analysis of urinary thromboxane B2 metabolites in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

A double blind placebo controlled crossover study of prostacyclin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Measurement of renal and non-renal eicosanoid synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Estimated rate of prostacyclin secretion into the circulation of normal man

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Clinical pharmacology of platelet cyclooxygenase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021

Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900683-5

7 January 2021